David Olmos

机构：Hospital Universitario 12 De Octubre · ORCID：0000-0002-7003-4826

发表论文 468 篇 · 总被引 20194 次 · h-index 65

代表论文

• Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 56)
• Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial (2025 · European Urology Oncology · 被引 30)
• Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. (2025 · Journal of Clinical Oncology · 被引 21)
• A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer (2025 · European Urology Oncology · 被引 10)
• Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. (2025 · Journal of Clinical Oncology · 被引 5)
• PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection? (2025 · European Urology Focus · 被引 2)